Appili Therapeutics Inc. (TSX: APLI)
Canada
· Delayed Price · Currency is CAD | Market Cap | 4.24M |
| Revenue (ttm) | 494.78K |
| Net Income (ttm) | -3.58M |
| Shares Out | 121.27M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,521 |
| Open | 0.0300 |
| Previous Close | 0.0350 |
| Day's Range | 0.0300 - 0.0350 |
| 52-Week Range | 0.0250 - 0.0600 |
| Beta | 0.95 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 11, 2024 |
About Appili Therapeutics
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a li... [Read more]
Financial Performance
In 2023, Appili Therapeutics's revenue was 827,407, an increase of 147.60% compared to the previous year's 334,177. Losses were -3.78 million, -59.09% less than in 2022.
Financial StatementsNews
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court's approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFA...
Appili Therapeutics reports Q2 results
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal mo...
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an im...
Appili Therapeutics Announces Results of Special Meeting of Shareholders
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: ...
Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an im...
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the N...
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy Presentati...
Appili Therapeutics – Press Release Correction
HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to its press release entitled “Appili Ther...
Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations with two existing program...
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders
Your vote is important no matter how many votes you hold. Shareholders who have questions or need assistance with voting their shares should contact info@appilitherapeutics.com
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today provided an update...
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for i...
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations...
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: ...
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025
Definitive agreement with Aditxt, if approved by Appili shareholders, provides significant premium to shareholders and resources to advance key programs
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and its wholly-owned subsidi...
Appili Therapeutics Announces Second Amendment to Arrangement Agreement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: ...
Appili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge Loan
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: ...
Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submissi...
Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:...
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss. Stryve Foods posted adjusted loss of $1.90 per share, versus market estimate...
Aditxt signs agreement to acquire Appili Therapeutics
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today annou...
Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTIO...